The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
WELIREG (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
WELIREG
Date registered
Evaluation commenced
Decision date
Approval time
247 (255 working days)
Active ingredients
belzutifan
Registration type
NCE/NBE
Indication
WELIREG (belzutifan) is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery.